Hospitalizations of Children and Adolescents with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, July 2021–January 2022

MMWR Morbidity and Mortality Weekly Report, Год журнала: 2022, Номер 71(7), С. 271 - 278

Опубликована: Фев. 15, 2022

The first U.S. case of COVID-19 attributed to the Omicron variant SARS-CoV-2 (the virus that causes COVID-19) was reported on December 1, 2021 (1), and by week ending 25, 2021, predominant circulating in United States.* Although COVID-19-associated hospitalizations are more frequent among adults,† can lead severe outcomes children adolescents (2). This report analyzes data from Coronavirus Disease 19-Associated Hospitalization Surveillance Network (COVID-NET)§ describe (aged 0-11 years) 12-17 during periods Delta (July 1-December 18, 2021) (December 19, 2021-January 22, 2022) predominance. During Delta- Omicron-predominant periods, rates weekly per 100,000 peaked weeks September 11, January 8, 2022, respectively. peak (7.1 100,000) four times (1.8), with largest increase observed aged 0-4 years.¶ monthly hospitalization rate unvaccinated years (23.5) six fully vaccinated (3.8). Strategies prevent adolescents, including vaccination eligible persons, critical.*.

Язык: Английский

---

Hospitalization of Infants and Children Aged 0–4 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 2020–February 2022

MMWR Morbidity and Mortality Weekly Report, Год журнала: 2022, Номер 71(11), С. 429 - 436

Опубликована: Март 15, 2022

The B.1.1.529 (Omicron) variant of SARS-CoV-2, the virus that causes COVID-19, has been predominant circulating in United States since late December 2021.* Coinciding with increased Omicron circulation, COVID-19-associated hospitalization rates rapidly among infants and children aged 0-4 years, a group not yet eligible for vaccination (1). Coronavirus Disease 19-Associated Hospitalization Surveillance Network (COVID-NET)† data were analyzed to describe hospitalizations U.S. years March 2020. During period predominance (December 19, 2021-February 2022), weekly per 100,000 peaked at 14.5 (week ending January 8, 2022); this Omicron-predominant peak was approximately five times during SARS-CoV-2 B.1.617.2 (Delta) (June 27-December 18, 2021, which week September 11, 2021).§ predominance, 63% hospitalized had no underlying medical conditions; <6 months accounted 44% hospitalizations, although differences observed indicators severity by age. Strategies prevent COVID-19 young are important include currently populations (2) such as pregnant women (3), family members, caregivers (4).

Язык: Английский

---

Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age

New England Journal of Medicine, Год журнала: 2022, Номер 386(21), С. 2011 - 2023

Опубликована: Май 11, 2022

Vaccination of children to prevent coronavirus disease 2019 (Covid-19) is an urgent public health need. The safety, immunogenicity, and efficacy the mRNA-1273 vaccine in 6 11 years age are unknown.Part 1 this ongoing phase 2-3 trial was open label for dose selection; part 2 observer-blinded, placebo-controlled expansion evaluation selected dose. In 2, we randomly assigned (6 age) a 3:1 ratio receive two injections (50 μg each) or placebo, administered 28 days apart. primary objectives were safety noninferiority immune response these that young adults (18 25 related 3 trial. Secondary included determination incidences confirmed Covid-19 severe acute respiratory syndrome infection, regardless symptoms. Interim analysis results reported.In trial, 751 received 50-μg 100-μg vaccine, on basis immunogenicity results, level 2. 4016 placebo followed median 82 (interquartile range, 14 94) after first injection. This associated with mainly low-grade, transient adverse events, most commonly injection-site pain, headache, fatigue. No vaccine-related serious multisystem inflammatory children, myocarditis, pericarditis reported as data-cutoff date. One month second injection (day 57), neutralizing antibody titer who at 1610 (95% confidence interval [CI], 1457 1780), compared 1300 CI, 1171 1443) adults, serologic responses least 99.0% participants both groups, findings met prespecified success criterion. Estimated 88.0% 70.0 95.8) against occurring more injection, time when B.1.617.2 (delta) dominant circulating variant.Two doses found be safe effective inducing preventing age; noninferior those adults. (Funded by Biomedical Advanced Research Development Authority National Institute Allergy Infectious Diseases; KidCOVE ClinicalTrials.gov number, NCT04796896.).

Язык: Английский

---

Hospitalizations of Children Aged 5–11 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 2020–February 2022

MMWR Morbidity and Mortality Weekly Report, Год журнала: 2022, Номер 71(16), С. 574 - 581

Опубликована: Апрель 19, 2022

On October 29, 2021, the Food and Drug Administration expanded Emergency Use Authorization for Pfizer-BioNTech COVID-19 vaccine to children aged 5-11 years; CDC's Advisory Committee on Immunization Practices' recommendation followed November 2, 2021.* In late December B.1.1.529 (Omicron) variant of SARS-CoV-2 (the virus that causes COVID-19) became predominant strain in United States,† coinciding with a rapid increase COVID-19-associated hospitalizations among all age groups, including years (1). COVID-19-Associated Hospitalization Surveillance Network (COVID-NET)§ data were analyzed describe characteristics 1,475 U.S. throughout pandemic, focusing period early Omicron predominance (December 19, 2021-February 28, 2022). Among 397 hospitalized during Omicron-predominant period, 87% unvaccinated, 30% had no underlying medical conditions, 19% admitted an intensive care unit (ICU). The cumulative hospitalization rate was 2.1 times as high unvaccinated (19.1 per 100,000 population) vaccinated¶ (9.2).** Non-Hispanic Black (Black) accounted largest proportion (34%) represented approximately one third this group. Children diabetes obesity more likely experience severe COVID-19. potential serious illness years, those health highlights importance vaccination Increasing coverage children, particularly racial ethnic minority groups disproportionately affected by COVID-19, is critical preventing outcomes.

Язык: Английский

---

Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents

New England Journal of Medicine, Год журнала: 2022, Номер 386(8), С. 713 - 723

Опубликована: Янв. 12, 2022

The increasing incidence of pediatric hospitalizations associated with coronavirus disease 2019 (Covid-19) caused by the B.1.617.2 (delta) variant severe acute respiratory syndrome 2 (SARS-CoV-2) in United States has offered an opportunity to assess real-world effectiveness BNT162b2 messenger RNA vaccine adolescents between 12 and 18 years age.

Язык: Английский

---

Postacute Sequelae of SARS-CoV-2 in Children

PEDIATRICS, Год журнала: 2024, Номер 153(3)

Опубликована: Фев. 7, 2024

The coronavirus disease 2019 (COVID-19) pandemic has caused significant medical, social, and economic impacts globally, both in the short long term. Although most individuals recover within a few days or weeks from an acute infection, some experience longer lasting effects. Data regarding postacute sequelae of severe respiratory syndrome 2 infection (PASC) children, COVID, are only just emerging literature. These symptoms conditions may reflect persistent (eg, cough, headaches, fatigue, loss taste smell), new like dizziness, exacerbation underlying conditions. Children develop de novo, including postural orthostatic tachycardia syndrome, myalgic encephalomyelitis/chronic fatigue autoimmune multisystem inflammatory children. This state-of-the-art narrative review provides summary our current knowledge about PASC prevalence, epidemiology, risk factors, clinical characteristics, mechanisms, functional outcomes, as well conceptual framework for based on National Institutes Health definition. We highlight pediatric components Health-funded Researching COVID to Enhance Recovery Initiative, which seeks characterize natural history, long-term health effects children young adults inform future treatment prevention efforts. initiatives include electronic record cohorts, offer rapid assessments at scale with geographical demographic diversity, longitudinal prospective observational estimate burden, illness trajectory, pathobiology, manifestations outcomes.

Язык: Английский

---

Characteristics and Clinical Outcomes of Children and Adolescents Aged <18 Years Hospitalized with COVID-19 — Six Hospitals, United States, July–August 2021

MMWR Morbidity and Mortality Weekly Report, Год журнала: 2021, Номер 70(5152), С. 1766 - 1772

Опубликована: Дек. 30, 2021

During June 2021, the highly transmissible† B.1.617.2 (Delta) variant of SARS-CoV-2, virus that causes COVID-19, became predominant circulating strain in United States. U.S. pediatric COVID-19-related hospitalizations increased during July-August 2021 following emergence Delta and peaked September 2021.§ As May 12, CDC recommended COVID-19 vaccinations for persons aged ≥12 years,¶ on November 2, were 5-11 years.** To date, clinical signs symptoms, illness course, factors contributing to period predominance have not been well described patients. partnered with six children's hospitals review medical record data patients <18 years 2021.†† Among 915 identified, 713 (77.9%) hospitalized (acute as primary or reason hospitalization), 177 (19.3%) had incidental positive SARS-CoV-2 test results (asymptomatic mild infection unrelated 25 (2.7%) multisystem inflammatory syndrome children (MIS-C), a rare but serious condition associated COVID-19.§§ 24.7% <1 year, 17.1% 1-4 years, 20.1% 38.1% 12-17 years. Approximately two thirds (67.5%) one more underlying conditions, obesity being most common (32.4%); among 61.4% obesity. 15.8% viral coinfection¶¶ (66.4% whom respiratory syncytial [RSV] infection). third (33.9%) <5 coinfection. 272 vaccine-eligible (aged years) (0.4%) was fully vaccinated.*** half (54.0%) received oxygen support, 29.5% admitted intensive care unit (ICU), 1.5% died; those requiring 14.5% required invasive mechanical ventilation (IMV). hospitalizations, many severe coinfections, few vaccinated, highlighting importance vaccination ≥5 other prevention strategies protect adolescents from particularly conditions.

Язык: Английский

---

Evaluating COVID-19 Vaccine Willingness and Hesitancy among Parents of Children Aged 5–11 Years with Chronic Conditions in Italy

Vaccines, Год журнала: 2022, Номер 10(3), С. 396 - 396

Опубликована: Март 4, 2022

COVID-19 vaccination has been extended to include children aged 5-11 years. This cross-sectional survey evaluated parental vaccine willingness and hesitancy, associated factors, for their years with chronic conditions. A telephone was conducted from 14 December 2021 4 January 2022. The questionnaire assessed participants' socio-demographic health-related information, attitudes towards infection, by using the PACV-5 (Parent Attitudes About Childhood Vaccines Survey Tool), sources of information. total 430 answers were collected anonymously. Respondents no cohabitant who had infected SARS-CoV-2 having vaccinated against a higher concern about severity COVID-19. parents' perceived risk that child could be in those more concerned COVID-19, an older child, at least one positive Only 38.8% parents willing vaccinate Parents did not need additional education, have whose older, received information on this physicians, self-reported SARS-CoV-2, expressed greater child. Overall, 26.3% high-hesitant, score ≥ 7. get vaccine, less educated, lower likely high-hesitant. New policies educational programs regarding conditions are needed reduce hesitancy increase uptake.

Язык: Английский

---

Parents' Hesitancy to Vaccinate Their 5–11-Year-Old Children Against COVID-19 in Saudi Arabia: Predictors From the Health Belief Model

Frontiers in Public Health, Год журнала: 2022, Номер 10

Опубликована: Март 30, 2022

Data exploring parents' hesitancy to vaccinate their 5-11-year-old children against COVID-19, and associated factors, is limited. This study aims investigate beliefs intentions using the Health Belief Model in Saudi Arabia. A national, cross-sectional, questionnaire-based was conducted November, 2021. The self-administered online questionnaire distributed a random sample of parents. Adult parents with at least one child were included. main outcome intention children. Variability assessed by demographics, COVID-19-related children's health status, constructs from Model. Univariate multivariable logistic regression used each factor adjust for intervariable effect on parental Of 4,135 participants, 61.9% hesitant Parents aged 31 40 years (OR = 1.23; 95% CI, 1.02-1.49) females 1.52; 1.25-1.84) had higher odds being than other groups. who perceived low benefit vaccine 16.3; 12.1-21.9) or safety efficacy concerns 3.76; 3.10-4.58) among most In conclusion, prevalent Arabia those minimal benefits lack COVID-19 more hesitant. Government efforts must be directed toward increasing awareness tackling through well-designed vaccination campaign.

Язык: Английский

---

Endotypes of Prematurity and Phenotypes of Bronchopulmonary Dysplasia: Toward Personalized Neonatology

Journal of Personalized Medicine, Год журнала: 2022, Номер 12(5), С. 687 - 687

Опубликована: Апрель 26, 2022

Bronchopulmonary dysplasia (BPD), the chronic lung disease of prematurity, is increasingly recognized as consequence a pathological reparative response developing to both antenatal and postnatal injury. According this view, pathogenesis BPD multifactorial heterogeneous with different patterns stress (endotypes) that combine varying insults might distinctively damage development airways, parenchyma, interstitium, lymphatic system, pulmonary vasculature. This results in clinical phenotypes BPD. There no clear consensus on which are endotypes prematurity but combination information placental bacteriological data enables identification two main pathways leading birth before 32 weeks gestation: (1) infection/inflammation (2) dysfunctional placentation. Regarding phenotypes, following have been proposed: parenchymal, peripheral airway, central interstitial, congestive, vascular, mixed phenotype. In line approach personalized medicine, endotyping phenotyping will facilitate design more targeted therapeutic prognostic approaches.

Язык: Английский

---